By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Horizon Discover today said it is collaborating with the Rosalind Franklin University of Medical Sciences to develop a human cellular disease model of cystic fibrosis.

The deal covers use of Horizon's Genesis precision genome editing technology to "reconstitute a specific mutation" in the cystic fibrosis transmembrane conductance regulator, or CFTR, protein in the endogenous genome of a lung cancer cell line.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.